卵巢腺癌细胞中TRAIL/TRAILR的表达变化  

Changes of expression levels of TRAIL/TRAILR system in ovarian adenocarcinoma cells

作　　者：李晓兰[1] 谢环[1] 邹敏[1] 刘云[1] 

机构地区：[1]三峡大学第二人民医院,湖北宜昌434000

出　　处：《中国妇幼保健》2016年第12期2549-2552,共4页Maternal and Child Health Care of China

基　　金：湖北省自然科学基金面上项目(2015CFB574);湖北宜昌自然科学基金(A11301-39)

摘　　要：目的分析TRAIL/TRAILR在卵巢腺癌细胞中的表达,探讨TRAIL/TRAILR系统在卵巢癌细胞凋亡中的作用。方法选择正常卵巢组织(对照组)、早期卵巢腺癌组织(EOC组)、复发的卵巢腺癌组织(ROC组)各30例,选取组织分为两份:分别用来进行免疫组织化学、蛋白质印迹法检测TRAIL及其受体蛋白质表达量的变化,并通过免疫组化法确定其表达部位。结果3组中TRAIL表达量无统计学差异(P>0.05);EOC组DR4、DR5表达量较对照组明显减少(P<0.01),ROC组DR4、DR5表达量较对照组、EOC组明显增加(P<0.01);EOC组DcR1、DcR2与对照组无统计学差异(P>0.05),ROC组DcR1、DcR2表达量较对照组、EOC组明显增加(P<0.01);EOC组OPG表达量与对照组比较无统计学差异(P>0.05);ROC组较对照组及EOC组明显减少(P<0.01)。TRAIL及受体阳性表达主要定位表达于卵巢癌腺上皮细胞、血管平滑肌及内皮细胞的细胞膜和胞浆等部位。结论1TRAIL在正常卵巢组织、早期卵巢腺癌及复发卵巢腺癌发展过程中的表达无明显变化;2在卵巢腺癌的早期,卵巢腺癌细胞死亡受体DR4,DR5表达明显减少,"诱骗"受体无显著变化,卵巢腺癌细胞凋亡过程中得以免疫耐受与被保护,引起卵巢腺癌细胞的凋亡逃逸,与卵巢腺癌的发生发展可能有关;在卵巢腺癌的晚期复发阶段,卵巢腺癌细胞的死亡受体DR4,DR5及"诱骗"受体DcR1,DcR2的表达均明显增加,OPG的表达显著减少,TRAIL/TRAILR系统显著失衡,卵巢腺癌细胞生长迅速,易发生转移。这一结果为TRAIL应用到临床治疗早期卵巢腺癌提供了依据,为治疗晚期复发的卵巢腺癌提出了进一步考证的必要性。3OPG与卵巢腺癌细胞的凋亡逃逸是否有关尚需进一步研究。Objective To analyze the expression levels of TRAIL/TRAILR system in ovarian adenocarcinoma cells, explore the role of TRAIL/TRAILR system in apoptosis of ovarian adenocarcinoma cells. Methods Ninety normal ovarian tissue specimens （ control group ） , early ovarian adenocareinoma tissue specimens （EOC group）, recurrent EOC tissue specimens （ROC group） were selected, respectively, 30 specimens in each group; each tissue was divided into two pieces for immunohistochemical staining and West blot detection respectively to determine TRAIL/TRAILR protein expression levels, and the expression was located by immunohistochemical staining. Results There was no statistically significant difference in the expression level of TRAIL among these three groups （ P〉0. 05 ） ; the expression levels of DR4 and DR5 decreased significantly in EOC group, there were statistically significant differences （P〈0. 01 ） , meanwhile, the expression levels of DR4 and DR5 increased significantly in ROC group compared with that in control group and EOC group, there were statistically significant differences （P〈0. 01 ） ; there was no statistically significant difference in DcR1 and DcR2 expression levels between EOC group and control group （ P〉0. 05 ） , while the expression levels of DcR1 and DcR2 increased significantly in ROC group compared with control group and EOC group, there were statistically significant differences （P〈0. 01 ） ; there was no statistically significant difference in OPG expression level be- tween EOC group and control group （ P〉0. 05 ） ; while they decreased sharply in ROC group compared with control group and EOC group, there were statistically significant differences （ P〈0. 01 ） . Most of TRAIL and its receptors located on the membrane and in the cytoplasm of ovarian adenocarcinoma glandular epithelium, vascular smooth muscle, and endothelial cells. Conclusion ＂ The expression of TRAIL in nor- mal ovarian tissue, early ovarian adenocarcinoma and recurrent ovarian adeno

关 键 词：卵巢腺癌 凋亡逃逸 TRAIL及其受体 

分 类 号：R737.33[医药卫生—肿瘤]